RT Journal Article
SR Electronic
T1 Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.20.21255825
DO 10.1101/2021.05.20.21255825
A1 Bochnia-Bueno, Lucas
A1 De Almeida, Sergio Monteiro
A1 Raboni, Sonia Mara
A1 Adamoski, Douglas
A1 Amadeu, Ludmilla Louise Moreira
A1 Carstensen, Suzana
A1 Nogueira, Meri Bordignon
YR 2021
UL http://medrxiv.org/content/early/2021/07/07/2021.05.20.21255825.abstract
AB Background This study aimed to calculate the seroconversion rate of the CoronaVac vaccine in healthcare workers (HCWs) after immunization.Methods Serum samples from 133 HCWs from Southern Brazil were collected one day before (Day 0) and +10, +20, +40, + 60, +110 days after administering the vaccine’s first dose. Immunoglobulin G (IgG) was quantified using immunoassays for anti-N-protein (nucleocapsid) antibodies (Abbott, Sligo, Ireland) and for anti-S1 (spike) protein antibodies (Euroimmun, Lübeck, Germany).Results Seroconversion by day 40 occurred in 129 (97%) HCWs for the S1 protein, and in 69 (51.87%) HCWs for the N protein. An absence of IgG antibodies (by both methodologies), occurred in two (1.5%) HCWs undergoing semiannual rituximab administration, and also in another two (1.5%) HCWs with no apparent reason.Conclusion This study showed that CoronaVac has a high seroconversion rate when evaluated in an HCW population.Funding This work was supported by the PROPLAN/Federal University of Paraná, Curitiba-Paraná, Brazil; FINEP, Funder of Studies and Projects, Ministry of Science, Technology and Innovation, Brazil Institutional Network, Project: Laboratories for Diagnostic Tests for COVID-19 (0494/20).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the PROPLAN/Federal University of Parana, Curitiba-Parana, Brazil; FINEP, Funder of Studies and Projects, Ministry of Science, Technology and Innovation, Brazil Institutional Network, Project: Laboratories for Diagnostic Tests for COVID-19 (0494/20).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:In total, 170 participants were recruited at the Complexo Hospital de Clinicas, UFPR, Clinical Laboratory, Curitiba, Brazil, during the vaccination of healthcare worker in this city. The Complexo Hospital de Clinicas, UFPR, Institutional Ethical Committee approved the study (CAAE: 31687620.2.0000.0096), and all participants signed their consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available with the corresponding author.